Related Experiment Video
Updated: Mar 29, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
Exploring the Anti-Cervical Cancer Effect and Hepatotoxicity Risk of Gossypol Based on Untargeted Metabolomics and
Jinyan Li1,2, Parwen Parhat1, Yinglan Ma1
1State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China.
Abstract:
Objectives: This research sought to examine the impact of gossypol on cervical cancer tumors that have been transplanted subcutaneously in nude mice, as well as the associated risk of liver damage and its underlying mechanisms. Methods: A subcutaneous cervical cancer tumor model was established in nude mice using the cell suspension inoculation method. Tumor volume and morphological changes in various organs were observed, and the serum concentrations of IL-6, IL-10, and TNF-α were assessed. Protein expression was analyzed using Western blotting. Untargeted metabolomics was employed to identify differential metabolites in mouse liver tissues. Network toxicology was utilized to pinpoint common targets associated with gossypol and hepatotoxicity, followed by KEGG and GO enrichment analyses. Molecular docking was conducted to preliminarily explore the mechanisms underlying gossypol-induced liver injury. Results: Gossypol significantly suppressed the development of subcutaneous cervical cancer tumors in immunodeficient mice. The Western blotting technique results revealed that increasing doses of gossypol led to a reduction in the expression levels of PIK3R2, GRB2, and MAPK1, compared to the model group (p < 0.05). Untargeted metabolomics revealed 1464 metabolites, from which 9 distinct metabolites were selected for further analysis. Network toxicology results indicated that the hepatotoxicity-related targets of gossypol included MTOR, TNF, CASP3, BCL2L1, and BCL2. KEGG analysis suggested that the toxic mechanisms may be linked to pathways involved in malignancy, the HIF-1 signaling pathway, proteoglycans in cancer, apoptosis, and others. Conclusions: Gossypol demonstrates a significant therapeutic effect against cervical cancer; however, its hepatotoxicity risk, mediated through multiple targets and pathways, requires further investigation.
Insights
Gossypol effectively inhibits cervical cancer growth in mice but poses a hepatotoxicity risk. Further research is needed to understand the molecular mechanisms of gossypol-induced liver injury and its therapeutic potential.
Area of Science:
- Oncology
- Toxicology
- Pharmacology
Background:
- Cervical cancer remains a significant global health challenge.
- Gossypol, a natural compound, has shown potential anticancer properties.
- Understanding gossypol's efficacy and safety profile is crucial for therapeutic development.
Purpose of the Study:
- To evaluate gossypol's anti-cervical cancer effects in a mouse model.
- To investigate the risk and mechanisms of gossypol-induced liver damage.
- To identify molecular targets and pathways involved in gossypol's action and toxicity.
Main Methods:
- Subcutaneous cervical cancer xenograft model in nude mice.
- Assessment of tumor volume, organ morphology, and serum cytokines (IL-6, IL-10, TNF-α).
- Protein expression analysis (Western blotting), untargeted metabolomics, network toxicology, KEGG/GO enrichment, and molecular docking.
Main Results:
- Gossypol significantly suppressed cervical cancer tumor growth.
- Gossypol reduced expression of PIK3R2, GRB2, and MAPK1.
- Identified 1464 differential metabolites and key hepatotoxicity targets (MTOR, TNF, CASP3, BCL2L1, BCL2) and pathways (malignancy, HIF-1 signaling, apoptosis).
Conclusions:
- Gossypol exhibits significant therapeutic potential against cervical cancer.
- Gossypol-induced hepatotoxicity involves multiple targets and pathways.
- Further investigation is warranted to elucidate gossypol's mechanisms and optimize its clinical application.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Mutagenicity and Carcinogenicity
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Drug Toxicity: Risk factors
Pharmacogenetics of Drug Metabolism: Overview